Low-molecular-weight vascular-disrupting agents (VDAs) cause a pronounced shutdown in
blood flow to solid tumours, resulting in extensive tumour-cell necrosis, while they leave the …

Dynamic contrast enhanced MRI (DCE-MRI) enables the quantitative assessment of tumor
status and has found application in both pre-clinical tumor models as well as clinical …

Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) is now frequently
used in early clinical trial assessment of antiangiogenic and vascular disrupting compounds …

This article reviews the application of dynamic contrast-enhanced magnetic resonance
imaging in both clinical studies and early-phase trials of angiogenesis inhibitors. Emphasis …

A clear definition for vascular targeting agents (VTAs) and vascular disrupting agents (VDAs)
has separated the two as distinct methods of cancer treatment. VDAs differ from VTAs …

Lung cancer is the most common cause of cancer death worldwide, with most patients dying
with metastatic disease. The prognosis for the majority of patients remains poor. It is evident …

A functional vascular supply is critical for the continued growth and development of solid
tumors. It also plays a major role in metastatic spread of tumor cells. This importance has led …

A high probability of benefit is desirable to justify the choice of anti-angiogenic therapy from
an ever-expanding list of expensive new anticancer agents. However, biomarkers of …

Purpose Identifying suitable markers of biologic activity is important when assessing novel
compounds such as angiogenesis inhibitors to optimize the dose and schedule of therapy …

Purpose The aim of this study was to use intravoxel incoherent motion diffusion-weighted
imaging to discriminate subtypes of renal neoplasms and to assess agreement between …